Chronic Urticaria: Following Practice Guidelines.

Chronic Urticaria: Following Practice Guidelines.
Skin Therapy Lett. 2018 May;23(3):1-4
Authors: Westby EP, Lynde C, Sussman G
Abstract
Histamine is a key inflammatory player in the pathogenesis of urticaria, a mast-cell-driven disease characterized clinically by the development of wheals, angioedema, or both. Changes to the management of chronic spontaneous urticaria have recently been adopted due to increasing literature surrounding the efficacy and safety of up-dosing modern second-generation H1-antihistamines and the use of omalizamub, a biologic agent, as a third-line treatment. Given the prevalence of chronic urticaria and its impact on quality of life, this editorial aims to provide a summary of the proposed updated guidelines for the management of chronic urticaria as agreed upon at the 5th Consensus Conference on the Update and Revision of the EAACI/GA2LEN/EDF/WAO Guideline for Urticaria in Berlin in December 2016. The chronic urticaria treatment algorithm outlined here reflects the updates and revisions made by 43 international experts representing 40 societies from 25 countries. These guidelines have yet to be published and therefore will require approval by respective national and international boards before adoption.
PMID: 29772036 [PubMed - in process]

Source: Skin Therapy Letter - May 1, 2018 Category: Dermatology Authors: Westby EP, Lynde C, Sussman G Tags: Skin Therapy Lett Source Type: research